JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).
Yazar
Sharma, Maitreyi
Muntean, Alina
le Sourd, Samuel
Vaccaro, Gina M.
Taieb, Julien
Boku, Narikazu
Xiong, Huiling
Conti, Ilaria
Bang, Yung-Jue
Ozguroglu, Mustafa
Moehler, Markus H.
Ryu, Min-Hee
Lee, Keun-Wook
Coskun, Hasan Senol
Wong, Rachel
Chung, Hyun-Choel
Poltoratsky, Artem
Tsuji, Akihito
Yen, Chia-Jui
Üst veri
Tüm öğe kaydını gösterBağlantı
http://hdl.handle.net/20.500.12627/20330https://doi.org/10.1200/jco.2018.36.4_suppl.tps195
Koleksiyonlar
- Bildiri [64839]